about
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.ALMS1-deficient fibroblasts over-express extra-cellular matrix components, display cell cycle delay and are resistant to apoptosis.Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation.Metformin: a modulator of bevacizumab activity in cancer? A case reportBiomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.Metabolic effects of anti-angiogenic therapy in tumors.VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells.LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors.Lipoatrophy induced by subcutaneous insulin infusion: ultrastructural analysis and gene expression profiling.Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth.LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung CancerClinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyMetformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLCLKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiationLKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective
P50
Q33877467-F898878E-B40D-427E-AE16-E22F0F69C779Q33889416-C8DF6D83-3051-4F77-967D-FB3F273EC3FFQ34100946-4013C024-C5E7-4EC1-9BFB-E6D83E912053Q36214971-F2796AD6-BEC0-4D55-9EC3-EE4B19B0C30AQ37687273-2DDCB22B-4FE7-4030-B018-BBCBB554BF6EQ37975887-25BFBAF2-882E-4243-9172-CA4A8E37364DQ38941727-3B4FE505-774F-4182-A7D9-F12D36272AD6Q39001187-D61DF91E-6FB5-4889-9B66-7C158981B2A9Q39547351-70BF278F-FD66-4A82-97D2-A877721E3FC8Q48157665-6337F971-5FFA-4531-98F6-ED0C459EC446Q54427427-80BBD5C8-8E84-40E0-B834-42601A3EAC5DQ55342073-E305182B-5D17-4153-890B-BA076CE08BB2Q64251353-DA3A5336-720A-4CE1-BF0E-6F49BC3D6766Q90637002-40579439-AA1F-4CAE-A9F5-9160E7479DA9Q91159351-8AE9C6D6-DF80-44C5-9D05-651BA78E2646Q91484159-64D5B354-0209-412F-9DFF-C7E1B8E1AAAAQ91531744-2E3F2674-133C-4DEB-A0C8-EC91ED4B2D9A
P50
description
researcher ORCID ID = 0000-0002-2624-5060
@en
wetenschapper
@nl
name
Elisabetta Zulato
@ast
Elisabetta Zulato
@en
Elisabetta Zulato
@es
Elisabetta Zulato
@nl
type
label
Elisabetta Zulato
@ast
Elisabetta Zulato
@en
Elisabetta Zulato
@es
Elisabetta Zulato
@nl
prefLabel
Elisabetta Zulato
@ast
Elisabetta Zulato
@en
Elisabetta Zulato
@es
Elisabetta Zulato
@nl
P106
P1153
36186501200
P31
P496
0000-0002-2624-5060